Eli Lilly v. Qilu Pharmaceutical: REYVOW® Lasmiditan Patent Dispute Consolidated
Eli Lilly filed suit against Qilu Pharmaceutical in the District of New Jersey, asserting US12071423B2 covering its lasmiditan migraine tablet REYVOW®. Within 21 days, the court consolidated this action with a related earlier case (No. 24-05847) for all purposes, administratively terminating this docket.
REYVOW® Lasmiditan Patent Case Consolidated Into Earlier Lilly Action
On November 27, 2024, Eli Lilly & Company filed Civil Action No. 2:24-cv-10802 in the District of New Jersey against Qilu Pharmaceutical Co., Ltd., asserting infringement of US12071423B2. The patent covers lasmiditan, the active ingredient in REYVOW®, Lilly’s 5-HT1F receptor agonist approved for acute migraine treatment. The accused products are Qilu’s 50 mg and 100 mg tablet formulations, suggesting a generic entry challenge, likely under the Hatch-Waxman framework.
The case was short-lived as a standalone docket. On December 18, 2024 — just 21 days after filing — the court issued an order consolidating this action with the earlier-filed Civil Action No. 24-05847 for all purposes, including discovery, case management, and trial. Administrative termination of No. 24-10802 followed, with all future filings directed to the lead case. No merits ruling, claim construction, or cost determination was issued in this docket.
The rapid consolidation is consistent with standard Hatch-Waxman case management practice when multiple ANDAs for the same reference drug generate successive filings against different generic applicants, or when a second filing by the same patentee against the same defendant is folded into a live case. The public record for this docket does not disclose the precise procedural trigger — whether a second ANDA, an amended complaint, or a related declaratory judgment — leaving substantive analysis of the underlying dispute to the lead consolidated docket.
Filing to Case Consolidated in 21 days
Case resolved by consolidation order in 21 days — well below the median ANDA district court timeline
Case consolidated: what the court’s order means for both parties
Consolidation terminates the docket — not the dispute
Consolidation under Fed. R. Civ. P. 42(a) merges related actions before the same court into a single proceeding. The administrative termination of No. 24-10802 is a docket-management step — it does not dismiss Eli Lilly’s claims or resolve any substantive issue. All rights, claims, and defences survive in the lead case, No. 24-05847.
No merits disposedLilly retains full infringement claim in consolidated action
Eli Lilly’s assertion of US12071423B2 against Qilu’s 50 mg and 100 mg lasmiditan tablets continues in the lead docket. Consolidation typically benefits the patentee by streamlining scheduling, avoiding inconsistent rulings, and reducing duplicative discovery burdens across related ANDA challenges to the same drug.
Claims survive in lead caseQilu now litigates in a single, potentially multi-ANDA proceeding
For Qilu, consolidation means it faces Lilly’s patent claims within a coordinated case that may involve other generic applicants or related patents. Defence strategy, discovery scope, and trial scheduling will be governed by the lead case order. Qilu will need to monitor the No. 24-05847 docket for all substantive developments going forward.
Defend in lead docketREYVOW® patent protection reinforced by coordinated enforcement
Consolidated Hatch-Waxman litigation signals Lilly is actively defending REYVOW® against multiple generic entry attempts. A successful outcome in the lead case could delay generic lasmiditan entry, preserving exclusivity in the acute migraine market. Other generic filers should expect coordinated patent enforcement and a well-resourced litigation posture from Lilly.
Generic entry at riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eli Lilly & Company | Company | Pharmaceutical innovator — holder of US12071423B2 covering lasmiditan (REYVOW®)Search in Eureka ↗ |
| Defendant | Qilu Pharmaceutical Co., Ltd. | Company | Qilu Pharmaceutical Co., Ltd. — Chinese generic pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Christine Intromasso Gannon | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Patrick Steven Salamea | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Eli Lilly & CompanySearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is procedural rather than substantive: it consolidates two infringement actions for all purposes and directs administrative termination of this docket. The phrase ‘for all purposes, including discovery, case management, and trial’ confirms that no bifurcation is contemplated — liability and any remedy will be adjudicated together in the lead case. Neither party has received a merits ruling; the dispute over US12071423B2 and Qilu’s lasmiditan tablets remains live in Civil Action No. 24-05847.
US12071423B2 — Lasmiditan Tablet Formulations for Acute Migraine
US12071423B2, filed under application number US18/134747, covers lasmiditan — a selective 5-HT1F receptor agonist commercialised by Eli Lilly as REYVOW®. Lasmiditan was the first non-vasoconstricting acute migraine therapy approved by the FDA, offering an important option for patients with cardiovascular contraindications to triptans. The relatively recent application number suggests this patent may be part of a continuation or lifecycle management strategy around Lilly’s core lasmiditan IP estate.
For generic pharmaceutical companies, US12071423B2 represents a material barrier to lasmiditan market entry. Lilly’s willingness to assert it in consolidated federal litigation signals confidence in the patent’s enforceability and claim breadth. Competitors filing ANDAs for lasmiditan tablets will need to address this patent directly — either through Paragraph IV certifications, IPR petitions, or formulation design-arounds. The outcome of the consolidated case in No. 24-05847 will set a precedent affecting the entire generic lasmiditan competitive landscape.
Should you run an FTO analysis against US12071423B2?
Any generic pharmaceutical company, CDMO, or API manufacturer considering lasmiditan tablet development — particularly 50 mg or 100 mg oral solid dosage forms — should treat US12071423B2 as a primary FTO target. Lilly’s active enforcement posture in New Jersey federal court, now consolidated across multiple actions, signals that any ANDA-related market entry will be contested. An FTO gap analysis should assess claim coverage against specific formulation parameters and dosage strengths.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US12071423B2 against your product specifications, identify relevant prior art, and surface related continuation or divisional patents in Lilly’s lasmiditan portfolio that may present additional freedom-to-operate risk. Eureka can also flag active litigation dockets referencing this patent family, ensuring your regulatory and IP teams have a complete risk picture before advancing an ANDA filing.
Run a freedom-to-operate analysis on US12071423B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Lasmiditan Patent Cases in the District of New Jersey
Cases involving small-molecule migraine drug patents litigated under Hatch-Waxman in the District of New Jersey, including related lasmiditan and 5-HT1F receptor agonist disputes.
What this case signals for the lasmiditan and migraine drug IP landscape
Lilly’s coordinated enforcement across multiple dockets suggests a deliberate strategy to protect REYVOW® from generic erosion.
Consolidation signals multiple generic ANDA filings against REYVOW®
The rapid consolidation of two separate civil actions within 21 days is consistent with Hatch-Waxman practice where successive ANDA filings trigger successive lawsuits. Any company holding or contemplating an ANDA for lasmiditan should track Civil Action No. 24-05847 as the operative docket for claim scope and scheduling.
US12071423B2 is the key patent to monitor for lasmiditan FTO
With Lilly asserting US12071423B2 across consolidated actions, this patent represents a primary exclusivity barrier for generic lasmiditan entry. R&D and regulatory teams at generic firms should assess claim coverage against their specific formulation and dosage form before advancing ANDA filings.
Eli v Qilu — key questions answered
The case was consolidated into Civil Action No. 24-05847 and administratively terminated after 21 days. Eli Lilly had asserted US12071423B2, covering lasmiditan (REYVOW®) tablets, against Qilu’s 50 mg and 100 mg generic formulations. No merits ruling was issued; the infringement dispute continues in the lead consolidated docket.
Eli Lilly asserted US12071423B2, filed under application number US18/134747. The patent covers lasmiditan, the active ingredient in REYVOW®, a 5-HT1F receptor agonist approved for acute migraine treatment. Qilu’s accused products were 50 mg and 100 mg lasmiditan tablets.
Case consolidation under Fed. R. Civ. P. 42(a) merges related actions into a single proceeding. Administrative termination of the merged docket is a clerical step — it does not dismiss any claims. All substantive rights, including the plaintiff’s infringement claims, continue in the lead consolidated case.
The consolidated litigation is before the United States District Court for the District of New Jersey, proceeding under Civil Action No. 24-05847. The New Jersey district court is a common venue for Hatch-Waxman pharmaceutical patent cases given its proximity to major pharma operations.
The public record for Case No. 2:24-cv-10802 identifies Qilu’s accused products as 50 mg and 100 mg lasmiditan tablets — the same strengths as REYVOW®. This is consistent with an ANDA-based Hatch-Waxman challenge, though the docket does not expressly confirm the regulatory pathway. All substantive filings will appear in the consolidated lead case, No. 24-05847.
PatSnap Eureka searches patents and litigation data to answer instantly.